Type 2 diabetes (T2D) has been known as 'bi-hormonal disorder' since decades ago, the role of glucagon from α-cell has languished whereas β-cell taking center stage. Recently, numerous findings indicate that the defects of glucagon secretion get involve with development and exacerbation of hyperglycemia in T2D. Aberrant α-cell responses exhibit both fasting and postprandial states: hyperglucagonemia contributes to fasting hyperglycemia caused by inappropriate hepatic glucose production, and to postprandial hyperglycemia owing to blunted α-cell suppression. During hypoglycemia, insufficient counter-regulation response is also observed in advanced T2D. Though many debates still remained for exact mechanisms behind the dysregulation of α-cell in T2D, it is clear that the blockade of glucagon receptor or suppression of glucagon secretion from α-cell would be novel therapeutic targets for control of hyperglycemia. Whereas there have not been remarkable advances in developing new class of drugs, currently available glucagon-like peptide-1 and dipeptidyl peptidase-IV inhibitors could be options for treatment of hyperglucagonemia. In this review, we focus on α-cell dysfunction and therapeutic potentials of targeting α-cell in T2D.

Citations

Citations to this article as recorded by  

• An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect
  Vijaya Subramanian, Jonatan I. Bagger, Vinayak Harihar, Jens J. Holst, Filip K. Knop, Tina Villsbøll
  American Journal of Physiology-Endocrinology and Metabolism.2024; 326(2): E182.     CrossRef
• Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway
  Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
  Endocrinology and Metabolism.2024; 39(1): 98.     CrossRef
• Childhood Obesity, Diabetes, and Cardiovascular Disease Risk
  Mostafa Salama, Babu Balagopal, Ilene Fennoy, Seema Kumar
  The Journal of Clinical Endocrinology & Metabolism.2023; 108(12): 3051.     CrossRef
• Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
  William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum
  Diabetes.2022; 71(1): 1.     CrossRef
• Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
  William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum
  Diabetes Care.2022; 45(1): 3.     CrossRef
• Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum
  Marek Skrzypski, Paweł A. Kołodziejski, Ewa Pruszyńska-Oszmałek, Tatiana Wojciechowicz, Paulina Janicka, Małgorzata Krążek, Emilian Małek, Mathias Z. Strowski, Krzysztof W. Nowak
  International Journal of Molecular Sciences.2022; 23(17): 9807.     CrossRef
• A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
  Vijaya Subramanian, Jonatan I. Bagger, Jens J. Holst, Filip K. Knop, Tina Vilsbøll
  Frontiers in Physiology.2022;[Epub]     CrossRef
• Increased serum cystatin C levels and responses of pancreatic α- and β-cells in type 2 diabetes
  Hui-qing Yuan, Jia-xi Miao, Jia-ping Xu, Su-xiang Zhu, Feng Xu, Xiao-hua Wang, Chun-hua Wang, Chao Yu, Xue-qin Wang, Jian-bin Su, Dong-mei Zhang
  Endocrine Connections.2022;[Epub]     CrossRef
• Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
  Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
  Soyeon Yoo, Dongkyu Kim, Gwanpyo Koh
  Journal of Clinical Medicine.2021; 10(11): 2487.     CrossRef
• Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes
  Hong Wang, Jie Cao, Jian-bin Su, Xue-qin Wang, Xing Wang, Dong-mei Zhang, Xiao-hua Wang
  Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
• Angiopoietins stimulate pancreatic islet development from stem cells
  Soujanya S. Karanth, Shuofei Sun, Huanjing Bi, Kaiming Ye, Sha Jin
  Scientific Reports.2021;[Epub]     CrossRef
• A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
  Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 3567.     CrossRef
• The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
  María Sofía Martínez, Alexander Manzano, Luis Carlos Olivar, Manuel Nava, Juan Salazar, Luis D’Marco, Rina Ortiz, Maricarmen Chacín, Marion Guerrero-Wyss, Mayela Cabrera de Bravo, Clímaco Cano, Valmore Bermúdez, Lisse Angarita
  International Journal of Molecular Sciences.2021; 22(17): 9504.     CrossRef
• Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s
  William T. Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christopher L. Pin, Sheryl Sato, C. Bruce Verchere, Minna Woo, Norman D. Rosenblum, Norman Rosenblum, William Cefalu, Dana K. Andersen, Guillermo Arreaza-Rubín, Christine Dhara, Stephen P. Jame
  Canadian Journal of Diabetes.2021; 45(8): 697.     CrossRef
• The role of GIP in α-cells and glucagon secretion
  Kimberley El, Jonathan E. Campbell
  Peptides.2020; 125: 170213.     CrossRef
• Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes
  Muhammad Yazid Jalaludin, Margarita Barrientos-Pérez, Mona Hafez, Jane Lynch, Naim Shehadeh, Serap Turan, Daniel Weghuber
  Clinical Trials.2020; 17(1): 87.     CrossRef
• Recent advances in understanding the role of glucagon-like peptide 1
  Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi
  F1000Research.2020; 9: 239.     CrossRef
• Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study
  Irene Roncero-Ramos, Juan F. Alcala-Diaz, Oriol A. Rangel-Zuñiga, Francisco Gomez-Delgado, Rosa Jimenez-Lucena, Antonio García-Rios, Cristina Vals-Delgado, Cristina Romero-Baldonado, Raul M. Luque, Jose M. Ordovas, Pablo Perez-Martinez, Antonio Camargo, J
  Clinical Nutrition.2020; 39(2): 492.     CrossRef
• Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
  Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
  Diabetes, Obesity and Metabolism.2020; 22(2): 173.     CrossRef
• Pathophysiology of Type 2 Diabetes in Children and Adolescents
  Badhma Valaiyapathi, Barbara Gower , Ambika P. Ashraf
  Current Diabetes Reviews.2020; 16(3): 220.     CrossRef
• Decellularized Tissue Matrix Enhances Self-Assembly of Islet Organoids from Pluripotent Stem Cell Differentiation
  Huanjing Bi, Soujanya S. Karanth, Kaiming Ye, Roland Stein, Sha Jin
  ACS Biomaterials Science & Engineering.2020; 6(7): 4155.     CrossRef
• Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
  Dipeeka K. Mandaliya, Sriram Seshadri
  Pancreatology.2019; 19(4): 617.     CrossRef
• A contemporary biological pathway of islet amyloid polypeptide for the management of diabetic dementia
  Sushil Kumar Sah, Vijaya Paul Samuel, Sunita Dahiya, Yogendar Singh, Ritu M. Gilhotra, Gaurav Gupta, Anurag Mishra, Rakesh Kumar Sharma, Gubbiyappa Shiva Kumar, Nagaraja SreeHarsha, Dinesh Kumar Chellappan, Kamal Dua
  Chemico-Biological Interactions.2019; 306: 117.     CrossRef
• Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
  Dipeeka K. Mandaliya, Sriram Seshadri
  Pancreatology.2019; 19(2): 280.     CrossRef
• Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients
  Minyoung Lee, Minkyung Kim, Jong Suk Park, Sangbae Lee, Jihong You, Chul Woo Ahn, Kyung Rae Kim, Shinae Kang
  The Korean Journal of Internal Medicine.2019; 34(5): 1068.     CrossRef
• Insulin regulates glucagon-like peptide-1 secretion by pancreatic alpha cells
  Pan Liu, Jia Song, He Liu, Fei Yan, Tianyi He, Lingshu Wang, Huying Shen, Xinguo Hou, Li Chen
  Endocrine.2018; 62(2): 394.     CrossRef
• Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential
  Ana Marta de Matos, Maria Paula de Macedo, Amélia Pilar Rauter
  Medicinal Research Reviews.2018; 38(1): 261.     CrossRef
• Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes
  Irene Roncero-Ramos, Rosa Jimenez-Lucena, Juan F. Alcala-Diaz, Cristina Vals-Delgado, Antonio P. Arenas-Larriva, Oriol A. Rangel-Zuñiga, Ana Leon-Acuña, María M. Malagon, Javier Delgado-Lista, Pablo Perez-Martinez, Jose M. Ordovas, Antonio Camargo, Jose L
  The Journal of Nutritional Biochemistry.2018; 62: 247.     CrossRef
• Targetting PED/PEA-15 for diabetes treatment
  Francesca Fiory, Rosa Spinelli, Gregory Alexander Raciti, Luca Parrillo, Vittoria D’esposito, Pietro Formisano, Claudia Miele, Francesco Beguinot
  Expert Opinion on Therapeutic Targets.2017; 21(6): 571.     CrossRef
• PANCREATIC ALPHA CELL DYSFUNCTION IN DIABETES MELLITUS AND ITS MANAGEMENT STRATEGIES
  Butungeshwar Pradhan, Chakradhar Majhi
  Journal of Evidence Based Medicine and Healthcare.2017; 4(45): 2775.     CrossRef
• Glucagon and heart in type 2 diabetes: new perspectives
  Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda
  Cardiovascular Diabetology.2016;[Epub]     CrossRef
• Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes
  Sivaram Pillarisetti
  Trends in Pharmacological Sciences.2016; 37(3): 207.     CrossRef
• The biology of glucagon and the consequences of hyperglucagonemia
  Nicolai J Wewer Albrechtsen, Rune E Kuhre, Jens Pedersen, Filip K Knop, Jens J Holst
  Biomarkers in Medicine.2016; 10(11): 1141.     CrossRef
• Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
  Chloé Amouyal, Fabrizio Andreelli
  Journal of Diabetes Research.2016; 2016: 1.     CrossRef
• Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1
  Toya M Albury-Warren, Veethika Pandey, Lina P Spinel, Michal M Masternak, Deborah A Altomare
  Journal of Endocrinology.2016; 228(1): 49.     CrossRef
• Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
  Hao Liu, Yun Hu, Feng-fei Li, Bing-li Liu, Xiao-fei Su, Jian-hua Ma
  Diabetes Therapy.2016; 7(4): 743.     CrossRef